Login now to access Regular content available to all registered users.
Abstract
Introduction: Preventing Zika Virus (ZIKV) infection by vaccinating women may decrease risk of congenital Zika syndrome. Clinical trials are underway for inactivated, live attenuated, and DNA ZIKV vaccines. We sought to describe pregnant women's attitudes toward participation in ZIKV vaccine research involving different vaccine platforms and to identify participation predictors and barriers.
Methods: Women attending prenatal care in June and July 2017 were offered enrollment in an anonymous survey which asked women their views about participating in hypothetical ZIKV vaccine research scenarios during pregnancy. Demographics and Zika exposure during pregnancy were obtained.
Results: Of 129 women, 70% expressed concern about ZIKV infection during pregnancy and 44% changed travel plans. Given the study scenarios, 68% stated they would consider an inactivated vaccine trial compared to 19% willing to participate in a live attenuated vaccine trial (p-value
Methods: Women attending prenatal care in June and July 2017 were offered enrollment in an anonymous survey which asked women their views about participating in hypothetical ZIKV vaccine research scenarios during pregnancy. Demographics and Zika exposure during pregnancy were obtained.
Results: Of 129 women, 70% expressed concern about ZIKV infection during pregnancy and 44% changed travel plans. Given the study scenarios, 68% stated they would consider an inactivated vaccine trial compared to 19% willing to participate in a live attenuated vaccine trial (p-value
Introduction: Preventing Zika Virus (ZIKV) infection by vaccinating women may decrease risk of congenital Zika syndrome. Clinical trials are underway for inactivated, live attenuated, and DNA ZIKV vaccines. We sought to describe pregnant women's attitudes toward participation in ZIKV vaccine research involving different vaccine platforms and to identify participation predictors and barriers.
Methods: Women attending prenatal care in June and July 2017 were offered enrollment in an anonymous survey which asked women their views about participating in hypothetical ZIKV vaccine research scenarios during pregnancy. Demographics and Zika exposure during pregnancy were obtained.
Results: Of 129 women, 70% expressed concern about ZIKV infection during pregnancy and 44% changed travel plans. Given the study scenarios, 68% stated they would consider an inactivated vaccine trial compared to 19% willing to participate in a live attenuated vaccine trial (p-value
Methods: Women attending prenatal care in June and July 2017 were offered enrollment in an anonymous survey which asked women their views about participating in hypothetical ZIKV vaccine research scenarios during pregnancy. Demographics and Zika exposure during pregnancy were obtained.
Results: Of 129 women, 70% expressed concern about ZIKV infection during pregnancy and 44% changed travel plans. Given the study scenarios, 68% stated they would consider an inactivated vaccine trial compared to 19% willing to participate in a live attenuated vaccine trial (p-value
Pregnant Women's Attitudes Toward Zika Virus Vaccine Study Participation
Ilona Goldfarb
Abstract
Introduction: Preventing Zika Virus (ZIKV) infection by vaccinating women may decrease risk of congenital Zika syndrome. Clinical trials are underway for inactivated, live attenuated, and DNA ZIKV vaccines. We sought to describe pregnant women's attitudes toward participation in ZIKV vaccine research involving different vaccine platforms and to identify participation predictors and barriers.
Methods: Women attending prenatal care in June and July 2017 were offered enrollment in an anonymous survey which asked women their views about participating in hypothetical ZIKV vaccine research scenarios during pregnancy. Demographics and Zika exposure during pregnancy were obtained.
Results: Of 129 women, 70% expressed concern about ZIKV infection during pregnancy and 44% changed travel plans. Given the study scenarios, 68% stated they would consider an inactivated vaccine trial compared to 19% willing to participate in a live attenuated vaccine trial (p-value
Methods: Women attending prenatal care in June and July 2017 were offered enrollment in an anonymous survey which asked women their views about participating in hypothetical ZIKV vaccine research scenarios during pregnancy. Demographics and Zika exposure during pregnancy were obtained.
Results: Of 129 women, 70% expressed concern about ZIKV infection during pregnancy and 44% changed travel plans. Given the study scenarios, 68% stated they would consider an inactivated vaccine trial compared to 19% willing to participate in a live attenuated vaccine trial (p-value
Introduction: Preventing Zika Virus (ZIKV) infection by vaccinating women may decrease risk of congenital Zika syndrome. Clinical trials are underway for inactivated, live attenuated, and DNA ZIKV vaccines. We sought to describe pregnant women's attitudes toward participation in ZIKV vaccine research involving different vaccine platforms and to identify participation predictors and barriers.
Methods: Women attending prenatal care in June and July 2017 were offered enrollment in an anonymous survey which asked women their views about participating in hypothetical ZIKV vaccine research scenarios during pregnancy. Demographics and Zika exposure during pregnancy were obtained.
Results: Of 129 women, 70% expressed concern about ZIKV infection during pregnancy and 44% changed travel plans. Given the study scenarios, 68% stated they would consider an inactivated vaccine trial compared to 19% willing to participate in a live attenuated vaccine trial (p-value
Methods: Women attending prenatal care in June and July 2017 were offered enrollment in an anonymous survey which asked women their views about participating in hypothetical ZIKV vaccine research scenarios during pregnancy. Demographics and Zika exposure during pregnancy were obtained.
Results: Of 129 women, 70% expressed concern about ZIKV infection during pregnancy and 44% changed travel plans. Given the study scenarios, 68% stated they would consider an inactivated vaccine trial compared to 19% willing to participate in a live attenuated vaccine trial (p-value
{{ help_message }}
{{filter}}